enGene Therapeutics Inc. (ENGN): who owns it and who trades it
As of Nov 16, 2026, ENGN insiders reported 1 purchase worth $10.1K in the last 12 months. The largest buyer was William Grossman (Director), with $10.1K. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling enGene Therapeutics
From the latest filingsOverall: more buying than selling. Insiders mostly bought. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ENGN
56 funds and institutions reported ENGN shares worth $66.6M at the end of Q2 2026, about 57% of the company. The largest holder is BML Capital Management, LLC with 10.0%.
Funds and institutions (13F) 57%Everyone else 43%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BML Capital Management, LLC | 6.67M | 9.96% | $11.5M | – |
| Siren, L.L.C. | 6.26M | 9.34% | $10.8M | – |
| Perceptive Advisors LLC | 4.82M | 7.20% | $8.3M | – |
| Ameriprise Financial Inc | 2.68M | 3.99% | $4.6M | – |
| Nextech Invest Ltd. | 2.32M | 3.47% | $4M | – |
| ADAR1 Capital Management, LLC | 2.10M | 3.14% | $3.6M | – |
| Vestal Point Capital, LP | 1.67M | 2.49% | $2.9M | – |
| Acorn Capital Advisors, LLC | 1.27M | 1.90% | $2.2M | – |
| Peapod Lane Capital LLC | 1.10M | 1.65% | $1.9M | – |
| Balyasny Asset Management L.P. | 1.01M | 1.50% | $1.7M | – |
| Millennium Management LLC | 966,627 | 1.44% | $1.7M | – |
| Renaissance Technologies LLC | 829,700 | 1.24% | $1.4M | – |
| Citadel Advisors LLC | 717,686 | 1.07% | $1.2M | – |
| Affinity Asset Advisors, LLC | 600,000 | 0.90% | $1M | – |
| UBS Group AG | 509,087 | 0.76% | $881K | – |
| Eversept Partners, LP | 469,584 | 0.70% | $812K | – |
| Kynam Capital Management, LP | 457,855 | 0.68% | $792K | – |
| Seven Fleet Capital Management LP | 411,065 | 0.61% | $711K | – |
| Jane Street Group, LLC | 382,459 | 0.57% | $662K | – |
| Rangeley Capital, LLC | 305,102 | 0.46% | $528K | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ENGN insiders reported $10.1K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 22, 2026 | William Grossman | Director | Purchase | 5,102 | $1.97 | $10.1K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| William Grossman | Interim Chief Medical Officer, Director | $10.1K | – | Sep 22, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ENGN short interest
Low short interest. 2.4% of ENGN shares are sold short: about 1 share in 41. Over the last 12 reports the number of shares short went up 12%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 1.62M ENGN shares were sold short, 2.4% of the shares outstanding, up 8.1% from the report before. At the average daily volume of 847,021 shares, buying them all back would take about 1.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 1.62M | 2.42% | +8% | 847,021 | 1.9 |
| Oct 15, 2026 | 1.50M | 2.24% | +8% | 801,510 | 1.9 |
| Sep 30, 2026 | 1.39M | 2.08% | +16% | 770,258 | 1.8 |
| Sep 15, 2026 | 1.20M | 1.79% | -2% | 700,551 | 1.7 |
| Aug 31, 2026 | 1.23M | 1.83% | -18% | 688,120 | 1.8 |
| Aug 14, 2026 | 1.50M | 2.23% | -14% | 680,801 | 2.2 |
| Jul 31, 2026 | 1.73M | 2.59% | +6% | 680,561 | 2.5 |
| Jul 15, 2026 | 1.64M | 2.45% | +44% | 1.26M | 1.3 |
| Jun 30, 2026 | 1.14M | 1.70% | -18% | 1.12M | 1.0 |
| Jun 15, 2026 | 1.39M | 2.08% | -14% | 859,253 | 1.6 |
| May 29, 2026 | 1.62M | 2.42% | +11% | 1.47M | 1.1 |
| May 15, 2026 | 1.46M | 2.17% | -27% | 5.75M | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
enGene Therapeutics company events
enGene Therapeutics filed 15 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Nov 12, 2026.
- Nov 12, 2026AnnouncementBelow is incorporated herein by reference. Filing
- Sep 8, 2026ResultsReleased financial results. Filing
- Aug 11, 2026AnnouncementEnGene Therapeutics Inc. hosted a virtual key opinion leader event to discuss emerging non-muscle invasive bladder cancer market research insights. Filing
- Jul 17, 2026AnnouncementShared information with investors. Filing
- Jul 16, 2026LeadershipDr. Richard Glickman resigned as a director and chairman of the Board of Directors of enGene Therapeutics Inc., including as a member of any committee of the Board. Filing
- Jun 18, 2026LeadershipAmended an earlier report. The information set forth in Item 2.05 of this Current Report on Form 8-K/A is incorporated herein by reference as if set forth herein. Filing
- Jun 15, 2026LeadershipDr. Hussein Sweiti notified the Company of his resignation from his position as Chief Medical Officer and Head of Research and Development of the Company, with his resignation to be effective as of June 14, 2026. Filing
- Jun 10, 2026VoteReported shareholder vote results. Filing
- May 7, 2026LeadershipEnGene USA, Inc., an indirect, wholly-owned subsidiary of enGene Therapeutics Inc. and Dr. Hussein Sweiti entered into an Amended and Restated Employment Agreement, effective as of May 6, 2026, which amended and restated in its entirety the Employment Agreement, dated September 29, 2025, between… Filing
- Apr 9, 2026RulesChanged its bylaws or articles. Filing
- Mar 9, 2026AgreementEnGene Holdings Inc. entered into a sales agreement with Leerink Partners LLC, pursuant to which the Company may sell its common shares, without par value, from time to time through Leerink Partners. Filing
- Mar 9, 2026ResultsReleased financial results. Filing
- Jan 21, 2026AgreementEnGene Holdings Inc. (the “Company”, and together with its subsidiaries enGene Inc. and enGene USA, Inc., collectively, the “Borrower”) entered into a Second Amendment to its Amended and Restated Loan and Security Agreement, dated December 22, 2023, by and among the Borrower, Hercules Capital… Filing
- Jan 21, 2026AnnouncementShared information with investors. Filing
- Dec 22, 2025ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
enGene Therapeutics financials
Famous investors that hold ENGN
4 of the 50 well-known investors we track reported holding ENGN in their latest 13F filing. The largest position is Jim Simons's, worth $2.3M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 1.13M | $2.3M | 0.0% | +37% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 444,471 | $889K | 0.0% | -38% |
| Israel Englander · Millennium Management | Q3 2026 | 181,619 | $363K | 0.0% | -81% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 75,552 | $151K | 0.0% | +440% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named ENGN in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Perceptive Advisors LLC | 13G/A | 8.9% |
| Nov 16, 2026 | Perceptive Advisors LLC | 13G/A | 8.9% |
| Nov 13, 2026 | Eventide Asset Management, LLC | 13G | 5.1% |
| Nov 13, 2026 | Eventide Asset Management, LLC | 13G | 5.1% |
Questions about enGene Therapeutics Inc. (ENGN) stock
Who owns the most ENGN stock?
The largest reported owner of enGene Therapeutics Inc. (ENGN) is BML Capital Management, LLC, with 10.0% of the company. In total, 56 funds and institutions reported holding ENGN at the end of Q2 2026, together about 57% of the shares. See the largest owners.
Are ENGN insiders buying or selling?
In the last 12 months, ENGN insiders reported 1 open-market purchase worth $10.1K and no sales. The latest trade was on Sep 22, 2026. See every trade.
What is the short interest in ENGN?
As of Oct 30, 2026, 1.62M ENGN shares were sold short, 2.4% of the shares outstanding, up 8.1% from the report before. At the average daily volume of 847,021 shares, buying them all back would take about 1.9 trading days (days to cover). See the history.
Which famous investors hold ENGN?
4 of the 50 well-known investors we track reported ENGN in their latest 13F filing, including Jim Simons, Ken Griffin, Israel Englander. The largest position is worth $2.3M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.